secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-08-12T11:33:59+00:00
Accession:  0001326190-26-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q2 net loss $22.8M; initiates Phase 3 MASH trial, positive AUD data
-----------------------------------------------------------------------------

- Net loss $22.8M ($0.12/share) vs $22.1M ($0.27/share) in Q2 2025; R&D $18.7M, G&A $7.6M.
- Cash and investments $519M as of June 30, 2026; gross proceeds $225M from April 2026 offering.
- Initiated global PERFORMA Phase 3 MASH trial; 52-week data expected 2029; pemvidutide granted FDA Breakthrough Therapy.
- Positive topline RECLAIM Phase 2 AUD: significant reduction in heavy drinking days; Fast Track designation.
- Completed enrollment in RESTORE Phase 2 ALD trial; topline data expected H2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/0001326190-26-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000049/alt-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer